Skip to main content
BIO-FD&C CO.,LTD. logo

BIO-FD&C CO.,LTD. — Investor Relations & Filings

Ticker · 251120 ISIN · KR7251120002 KO Manufacturing
Open in API
Filings indexed 95 across all filing types
Latest filing 2022-01-27 Capital/Financing Update
Country KR South Korea
Listing KO 251120

About BIO-FD&C CO.,LTD.

https://www.biofdnc.com/?lang=en

BIO-FD&C CO.,LTD. is a biotechnology company specializing in research and development based on a proprietary, sustainable plant cell platform technology. The company develops and commercializes high-value active ingredients for the cosmetics, pharmaceutical, and food industries. Its product portfolio includes plant cell-derived materials, bioactive recombinant proteins, growth factors, and peptides, with a significant focus on anti-aging ingredients for cosmeceuticals. Leveraging advanced techniques such as bioreactor cultivation, radiofrequency-enhanced production of bioactive compounds (SMART-RC2), and plant cell cryopreservation, the company is also exploring the development of plant cell-based therapeutics, including antibodies and vaccines.

Recent filings

Filing Released Lang Actions
[기재정정]투자설명서
Capital/Financing Update Classification · 98% confidence The document is a 'Correction Report' (정정신고서) for a 'Securities Registration Statement' (투자설명서) filed by BioFD&C. It details amendments to the offering price, total offering amount, and allocation ratios following the determination of the final public offering price. In the context of Korean financial regulations (DART system), this is a formal regulatory filing related to an IPO process. Since it is a detailed amendment to a registration statement rather than a simple announcement of a report, it falls under the category of Regulatory Filings.
2022-01-27 Korean
투자설명서
Capital/Financing Update Classification · 95% confidence The document is a '투자설명서' (Investment Prospectus) for the company 'BioFD&C' (주식회사 바이오에프디엔씨). It contains detailed information regarding a public offering of 1,300,000 shares, including offering price, subscription periods, and comprehensive risk factors (business, industry, and financial risks). In the context of financial filings, a prospectus is a formal document provided to potential investors, which falls under the category of Proxy Solicitation & Information Statement (PSI) or, more broadly, regulatory offering materials. Given the specific options provided, 'PSI' is the most accurate classification for a document detailing an investment offering and associated disclosures.
2022-01-20 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) for the company '바이오에프디엔씨'. It details amendments to investment risk factors and the use of proceeds from a public offering. In the context of financial filings, a Securities Registration Statement (and its amendments) is a primary regulatory document for capital raising, which falls under the 'Regulatory Filings' category as it is a formal filing with the financial regulator (FSS in Korea) that does not fit into the specific categories like 10-K or Earnings Release.
2022-01-14 Korean
증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details the company's business, financial risks, and offering terms for a public offering of shares (IPO). This document is a formal regulatory filing required for companies planning to list on the KOSDAQ market. Among the provided categories, 'Regulatory Filings' (RNS) is the most appropriate fallback for this type of official registration statement.
2021-12-29 Korean
감사보고서 (2019.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'BioFD&C' (주식회사 바이오에프디엔씨) for the fiscal year ending December 31, 2019. It includes the independent auditor's opinion, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes. This is a comprehensive financial report, not an announcement or a summary, and fits the definition of an Audit Report/Information (AR) as it provides the results of the audit and the financial statements. FY 2019
2020-04-09 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.